Why the care you need doesn't exist yet

Healthcare systems commission new services when two conditions are met: clinical evidence of need and an economic case for investment. For integrated ADHD and reproductive health care, the first condition is becoming clearer. The second barely exists.

The clinical picture is this. Women with ADHD have roughly six to fifteen times the general population rate of PMDD. They face postpartum depression at five times the average rate. Adolescents with ADHD have approximately double the odds of early unintended pregnancy. The diagnostic delay, averaging 10 to 13 years longer than men, spans the most reproductively significant decade of women's lives. These patterns emerge consistently across Dutch outpatient, UK community, and Taiwanese prospective samples, suggesting they are not artifacts of specific healthcare contexts but structural features of the ADHD-reproductive health intersection wherever it occurs.

The economic picture is almost entirely absent.

The missing fiscal argument

Bäuml et al. (2023) conducted a cost-benefit analysis of ADHD intervention in Germany, finding that untreated ADHD was associated with an average per-capita lifetime earnings loss of approximately 92,000 euros, and projecting a societal cost of 2.93 billion euros from a single childhood cohort. The authors concluded that reasonably effective intervention could justify considerable public investment.

That analysis was built around ADHD broadly, and around a population that was not stratified by sex. No equivalent analysis exists for the female-specific, hormone-sensitive dimension of ADHD. The five-fold elevated postpartum depression rate has not been costed. The unintended pregnancies associated with ADHD-related contraceptive nonadherence have not been modeled. The healthcare utilization generated by a diagnostic delay spanning the reproductive window has not been calculated.

Without this fiscal evidence, commissioning bodies have no basis on which to fund integrated care. The fragmented system, where ADHD clinics do not ask about reproductive health and reproductive health services do not screen for ADHD, persists by default.

What the evidence base requires

Two things need to happen, and they are related.

The first is scale. The two most rigorous studies tracking ADHD symptoms prospectively across the menstrual cycle have a combined sample of approximately 140 participants. The Swedish registry study that provides the most compelling postpartum data drew on 773,000 women but contained no ADHD measures. Population-level evidence requires studies large enough to detect the associations that matter, and designed to measure both sides of the intersection simultaneously.

The second is an integrated measurement tool. A short instrument combining the ASRS for ADHD symptom baseline, prospective daily menstrual symptom diaries across at least two cycles, and items capturing contraceptive adherence and pregnancy intention would enable simultaneous ADHD and PMDD case-finding, distinguish stable neurodevelopmental impairment from cyclical hormonal amplification, and generate the data needed to build an economic case. Embedded in ADHD clinics, perinatal services, and reproductive health settings, it is feasible without costly hormone assays or specialist infrastructure.

What this means while you wait

The integrated service you need almost certainly does not exist in your healthcare system yet. Understanding why, that it is a commissioning and evidence problem, not a clinical impossibility, positions you to advocate more precisely for what you deserve.

When you push for your ADHD to be considered in reproductive health encounters, or for your cycle to be considered in ADHD assessment, you are asking for something the clinical evidence already supports. The systems have not caught up. That is a structural failure, not a reflection of the legitimacy of your need.

The data you collect about your own experience, how your ADHD shifts across your cycle, how your mood and cognition relate to your hormonal phases, belongs in clinical conversations. The Samphire app is designed to support that tracking. In aggregate, it also contributes to the evidence base this field needs.

Frequently asked questions

Why does integrated ADHD and reproductive health care not exist?

Integrated care requires both clinical evidence of need and an economic case for investment. The clinical evidence is accumulating but the economic analysis, modeling the cost of untreated ADHD-related reproductive health outcomes and the return on integrated intervention, has not been done. Without fiscal evidence, commissioning bodies have limited basis to fund new service configurations.

What would a sufficient evidence base look like?

Large-scale longitudinal studies integrating validated ADHD measures with prospective reproductive health data, combined with embedded cost data from the outset, would allow construction of the economic case commissioners need. A validated integrated screening tool combining the ASRS with prospective menstrual symptom diaries and contraceptive adherence items would generate population-level data across clinical settings without requiring specialist infrastructure.

Is the economic cost of ADHD in women significant enough to justify policy change?

The existing evidence strongly suggests yes, though the female-specific analysis remains to be done. Untreated ADHD broadly is associated with 92,000 euros per-capita lifetime earnings losses in existing analyses. Given the elevated rates of postpartum depression, PMDD, and unintended pregnancy associated with ADHD in women, each carrying substantial direct and indirect healthcare costs, the economic case, once modeled, is likely to be compelling.

What can I do now?

Track your symptoms prospectively across your cycle. Two cycles of daily data distinguishing ADHD symptoms, mood, and cycle phase gives you the longitudinal picture that supports informed clinical advocacy. The Samphire app supports this tracking and generates personalized insights across your hormonal cycle.